kabutan

Oncolys BioPharma Inc.(4588) Summary

4588
TSE Growth
Oncolys BioPharma Inc.
932
JPY
-22
(-2.31%)
Dec 5, 11:30 am JST
6.01
USD
Dec 4, 9:30 pm EST
Result
PTS
outside of trading hours
931.1
Dec 5, 11:29 am JST
Summary Chart Historical News Financial Result
PER
PBR
14.5
Yield
ー%
Margin Trading Ratio
1,106.35
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
939 JPY 6.05 USD
Previous Close Dec 4
954 JPY 6.14 USD
High Dec 5, 9:02 am
957 JPY 6.17 USD
Low Dec 5, 9:10 am
904 JPY 5.82 USD
Volume
1,128,800
Trading Value
1.05B JPY 6.77M USD
VWAP
929.46 JPY 5.99 USD
Minimum Trading Value
93,200 JPY 601 USD
Market Cap
0.03T JPY 0.16B USD
Number of Trades
2,341
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
High
1-Year Average
1,603
1-Year High Oct 9, 2025
18,110
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 300 6,398,800 21329.33
Nov 21, 2025 17,200 6,049,200 351.70
Nov 14, 2025 600 5,858,800 9764.67
Nov 7, 2025 4,600 5,525,800 1201.26
Oct 31, 2025 1,600 5,535,500 3459.69
Company Profile
Oncolys BioPharma Inc. is a drug discovery venture focusing on rare cancers and severe infectious diseases, utilizing proprietary virus technology.
Sector
Pharmaceuticals
Oncolys BioPharma Inc. promotes the development of cancer virus therapy and severe infectious disease treatments using its proprietary virus genetic modification technology. Its main pipeline includes Telomelysin, which specifically proliferates in cancer cells, and OBP-702, a next-generation Telomelysin with even more potent anti-cancer activity. Additionally, OBP-601, which has been developed as an HIV infection treatment, is now being repurposed as a treatment for neurodegenerative diseases. The company is also developing OBP-2011 as a viral infection treatment. Oncolys BioPharma Inc. is also working on TelomeScan, a cancer diagnostic agent for ultra-early detection or prognosis testing of cancer. The company employs a fabless management strategy to optimize development efficiency and expenses.